/

Halozyme Therapeutics, Inc.

HALO US

HALO USHalozyme Therapeutics, Inc.

United States Composite

37.81

USD

-0.21

(-0.55%)

2.10EPS Dil.

17.72P/E

4.79BMarket Cap

Next Earnings

May 7

Held by Insiders

1.07%

Held by Institutions

100.11%

Short % of Float

6.37%

YTD Yield

14.39%

3Y Yield

-15.41%

5Y Yield

151.91%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

- -

LT Borrowings

1,496

1,498

1,499

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

132

127

Market Capitalization

4,756

5,045

4,685

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

766

879

746

Cash, Cash Equivalents & STI

348

483

336

Accounts Receivable, Net

228

220

233

Inventories

132

129

128

Total Current Liabilities

116

115

112

Payables & Accruals

116

115

112

ST Debt

- -

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

39.44%

41.11%

25.61%

Net Income, GAAP

-60.60%

-13.41%

39.60%

Free Cash Flow

-22.37%

55.10%

58.72%

Total Cash Common Dividend

- -

Total Equity

-123.76%

-6.55%

-50.59%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

136

116

102

443

2022

117

152

209

181

660

2023

162

221

216

230

829

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.20

0.64

1.53

0.48

2.86

2022

0.44

0.16

0.45

0.43

1.48

2023

0.29

0.57

0.62

0.66

2.13

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Full Time Employees: 373
Sector: Healthcare
Industry: Biotechnology
Address: 12390 El Camino Real San Diego CA United States 92130
Website: halozyme.com
Business: Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Company News

Yahoo
21 days ago
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Zacks
21 days ago
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Zacks
22 days ago
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Yahoo
22 days ago
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Zacks
23 days ago
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
Zacks
a month ago
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
Yahoo
a month ago
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Zacks
a month ago
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Zacks
a month ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Yahoo
a month ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Yahoo
a month ago
Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...
Yahoo
a month ago
Should You Hold Halozyme Therapeutics (HALO)?

Company Description

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Full Time Employees: 373
Sector: Healthcare
Industry: Biotechnology
Address: 12390 El Camino Real San Diego CA United States 92130
Website: halozyme.com
Business: Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Company News

Yahoo
21 days ago
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Zacks
21 days ago
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Zacks
22 days ago
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Yahoo
22 days ago
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
Zacks
23 days ago
Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?
Zacks
a month ago
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
Yahoo
a month ago
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Zacks
a month ago
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Zacks
a month ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Yahoo
a month ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Yahoo
a month ago
Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...
Yahoo
a month ago
Should You Hold Halozyme Therapeutics (HALO)?